Hematologic and clinical characteristics of patients stratified according to EZH2 mutational status
| . | PMF . | P . | PPV/PET-MF . | P . | ||
|---|---|---|---|---|---|---|
| EZH2 . | EZH2 . | |||||
| Wild-type . | Mutated . | Wild-type . | Mutated . | |||
| N | 348 | 22 | 141 | 7 | ||
| Median follow-up, mo, (range) (n = 500)* | 39.567 (1-340) | 28.183 (8-183) | .365 | 29.7 (1-234) | 16.8 (1-70) | .256 |
| Median age, y (range) | 60.0 (14-90) | 66.0 (38-90) | .135 | 62.0 (32-84) | 62.0 (52-78) | .731 |
| Male sex, no. (%) (n = 303)* | 221 (60.6) | 15 (68.2) | .481 | 73 (51.8) | 4 (57.1) | .781 |
| Leukocytes, × 106/L, mean ± SD (n = 500)* | 12.3 ± 13.3 | 18.7 ± 11.5 | .001 | 14.3 ± 14.1 | 13.8 ± 7.0 | .360 |
| Hb, g/L, mean ± SD (n = 497)* | 114 ± 27 | 112 ± 19 | .700 | 114 ± 26 | 100 ± 18 | .153 |
| Platelets, × 106/L, mean ± SD, (n = 501)* | 341.0 ± 345.6 | 405.0 ± 258.7 | .831 | 404.1 ± 317.6 | 232.1 ± 198.0 | .097 |
| Peripheral blast cells, %, mean ± SD (n = 329)* | 0.7 ± 2.1 | 1.6 ± 2.1 | .002 | 0.5 ± 2.0 | 0.4 ± 0.9 | .959 |
| Constitutional symptoms, no. (%) (n = 333)* | 67 (28.2) | 8 (42.1) | .198 | 34 (47.9) | 2 (40.0) | .733 |
| Splenomegaly, no. (%) (n = 494)*† | .016 | .059 | ||||
| 0 | 91 (27.6) | 1 (4.5) | 17 (12.6) | 3 (42.9) | ||
| 1 | 141 (42.7) | 9 (40.9) | 58 (43.0) | 1 (14.3) | ||
| 2 | 98 (29.7) | 12 (54.5) | 60 (44.4) | 3 (42.9) | ||
| Abnormal karyotype, no. (%) (n = 195)* | 26 (20.2) | 4 (36.4) | .209 | 17 (32.7) | 2 (66.7) | .229 |
| Unfavorable karyotype, no. (%) (n = 188)* | 18 (14.3) | 3 (27.3) | .252 | 11 (22.9) | 2 (66.7) | .092 |
| JAK2V617F, no. (%) (n = 518)* | 204 (58.8) | 9 (40.9) | .100 | 105 (74.5) | 3 (42.9) | .066 |
| JAK2V617F allele burden, %, mean ± SD | 45.7 ± 22.9 | 42.2 ± 22.1 | .603 | 64.1 ± 23.4 | 61.1 ± 52.6 | .747 |
| MPL W515L/K, no. (%) (n = 466)* | 13 (3.9) | 0 (0.0) | .344 | 5 (4.7) | 0 (0.0) | .586 |
| IWG-MRT score, no. (%) (n = 192)* | .002 | - | ||||
| Low | 55 (31.8) | 4 (21.1) | ||||
| Int-1 | 44 (25.4) | 5 (26.3) | ||||
| Int-2 | 43 (24.9) | 0 (0.0) | ||||
| High | 31 (17.9) | 10 (52.6) | ||||
| Progression to acute leukemia, no. (%) (n = 443)* | 57 (17.6) | 7 (31.8) | .098 | 16 (17.2) | 1 (20.0) | .872 |
| Death, no. (%) (n = 494)* | 86 (26.0) | 13 (61.9) | < .001 | 28 (20.6) | 1 (16.7) | .816 |
| . | PMF . | P . | PPV/PET-MF . | P . | ||
|---|---|---|---|---|---|---|
| EZH2 . | EZH2 . | |||||
| Wild-type . | Mutated . | Wild-type . | Mutated . | |||
| N | 348 | 22 | 141 | 7 | ||
| Median follow-up, mo, (range) (n = 500)* | 39.567 (1-340) | 28.183 (8-183) | .365 | 29.7 (1-234) | 16.8 (1-70) | .256 |
| Median age, y (range) | 60.0 (14-90) | 66.0 (38-90) | .135 | 62.0 (32-84) | 62.0 (52-78) | .731 |
| Male sex, no. (%) (n = 303)* | 221 (60.6) | 15 (68.2) | .481 | 73 (51.8) | 4 (57.1) | .781 |
| Leukocytes, × 106/L, mean ± SD (n = 500)* | 12.3 ± 13.3 | 18.7 ± 11.5 | .001 | 14.3 ± 14.1 | 13.8 ± 7.0 | .360 |
| Hb, g/L, mean ± SD (n = 497)* | 114 ± 27 | 112 ± 19 | .700 | 114 ± 26 | 100 ± 18 | .153 |
| Platelets, × 106/L, mean ± SD, (n = 501)* | 341.0 ± 345.6 | 405.0 ± 258.7 | .831 | 404.1 ± 317.6 | 232.1 ± 198.0 | .097 |
| Peripheral blast cells, %, mean ± SD (n = 329)* | 0.7 ± 2.1 | 1.6 ± 2.1 | .002 | 0.5 ± 2.0 | 0.4 ± 0.9 | .959 |
| Constitutional symptoms, no. (%) (n = 333)* | 67 (28.2) | 8 (42.1) | .198 | 34 (47.9) | 2 (40.0) | .733 |
| Splenomegaly, no. (%) (n = 494)*† | .016 | .059 | ||||
| 0 | 91 (27.6) | 1 (4.5) | 17 (12.6) | 3 (42.9) | ||
| 1 | 141 (42.7) | 9 (40.9) | 58 (43.0) | 1 (14.3) | ||
| 2 | 98 (29.7) | 12 (54.5) | 60 (44.4) | 3 (42.9) | ||
| Abnormal karyotype, no. (%) (n = 195)* | 26 (20.2) | 4 (36.4) | .209 | 17 (32.7) | 2 (66.7) | .229 |
| Unfavorable karyotype, no. (%) (n = 188)* | 18 (14.3) | 3 (27.3) | .252 | 11 (22.9) | 2 (66.7) | .092 |
| JAK2V617F, no. (%) (n = 518)* | 204 (58.8) | 9 (40.9) | .100 | 105 (74.5) | 3 (42.9) | .066 |
| JAK2V617F allele burden, %, mean ± SD | 45.7 ± 22.9 | 42.2 ± 22.1 | .603 | 64.1 ± 23.4 | 61.1 ± 52.6 | .747 |
| MPL W515L/K, no. (%) (n = 466)* | 13 (3.9) | 0 (0.0) | .344 | 5 (4.7) | 0 (0.0) | .586 |
| IWG-MRT score, no. (%) (n = 192)* | .002 | - | ||||
| Low | 55 (31.8) | 4 (21.1) | ||||
| Int-1 | 44 (25.4) | 5 (26.3) | ||||
| Int-2 | 43 (24.9) | 0 (0.0) | ||||
| High | 31 (17.9) | 10 (52.6) | ||||
| Progression to acute leukemia, no. (%) (n = 443)* | 57 (17.6) | 7 (31.8) | .098 | 16 (17.2) | 1 (20.0) | .872 |
| Death, no. (%) (n = 494)* | 86 (26.0) | 13 (61.9) | < .001 | 28 (20.6) | 1 (16.7) | .816 |